January 6, 2026 4:43pm

Tail winds drive indexes and the C&GT’s sector, Tuesday versus Monday’s stymied its sliding share pricing, it was due; however, jobs week kick-offs Wednesday

Pre-open Signal Results: 4 Hits and 0 Miss

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW and why! 

This week features a wide-ranging economic data calendar building to Friday's December jobs report, which will provide the final employment snapshot of 2025 and potentially influence Fed bank’s policy expectations after the hawkish December meeting

RMi Pre-opening: Waiting to be judged … https://www.regmedinvestors.com/articles/14255

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Tuesday: The Dow closed UP +484.90 points or +0.99%, the S&P closed UP +42.67 points or +0.62% while the Nasdaq closed UP +151.351 points or +0.65%

  • Theme of the session: stocks related to Ai supported the broader market

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • Service-sector activity in December fell to its slowest pace in 8 months, S&P Global reported the firm’s headline services PMI declined to 52.5 for the month, down from 54.1 in November and below the consensus estimate for 53.0. The diffusion index represents the % of companies reporting expansion, so anything above 50 indicates growth, albeit at a slower pace in the case of December.

Tuesday’s (my) 40-company covered sector’s advance/decline line opened positive with 29 incliners, 8 decliners and 3 flats ending with a positive close of 27 incliners, 11 decliners and 2 flats

The CBOE Fear (VIX) index, Tuesday closed at 14.77 after Monday closed at 14.91, Friday’s 14.46, Thursday was closed New Years Day, Wednesday at 15.03 and last Tuesday closed at 14.

Metrics: Tuesday …

  • The RUT was up +34.98 points or +1.37%,
  • The XLV was up +3.07 points or +%,
  • The NBI was up +127.96 points or +2.278%;
  • The XBI was up +1.94 points or +0.61%
  • The IWM was up +3.35 or +1.33%;
  • The IBB was up +3.90 points or +2.33%,
  • The VIX was down -0.13 points or -0.87% at to 14.77`

 

Q1/26 – 1 holiday, 1 negative and 2 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Tuesday Closing UP (10 of 27) +$ after Monday’s

  • Vertex (VRTX +$19.58 after Monday’s -$3.33 after Friday’s -$1.23),
  • Alnylam Pharmaceuticals (ALNY +$8.57 after Monday’s -$2.34 after Friday’s +$2.52),
  • Arrowhead Pharmaceuticals (ARWR +$5.93 after Monday’s -$3.91 after Friday’s +$1.40),
  • IQAA Holdings (IQV +$5.91 after Monday’s +$9.27),
  • Moderna (MRNA +$3.49 after Monday’s +$1.31 after Friday’s +$11.37),
  • CRISPR Therapeutics (CRSP +$3.03 after Monday’s +$1.38 after Friday’s +$1.33),
  • Ionis Pharmaceuticals (IONS +$2.96 after Monday’s -$1.14 after Friday’s +$0.56),
  • Vericel (VCEL +$2.26 after Monday’s +$1.47 after Friday’s -$0.40),
  • Beam Therapeutics (BEAM +$1.50 after Monday’s -$0.30 after Friday’s -$0.58),
  • Capricor Therapeutics (CAPR +$1.30 after Monday’s -$3.50 after Friday’s -$0.55),

Flat (2)

  • Adverum Biotechnologies ADVM) – acquired
  • Fate Therapeutics (FATE)

Tuesday’s Closing DOWN (11 of 11): 

  • AxoGen (AXGN -$0.71 after Monday’s +$0.76 after Friday’s -$1.73),
  • Ultragenyx Pharmaceuticals (RARE -$0.57 after Monday’s -$0.49 after Friday’s +$0.60),
  • Entrada Therapeutics (TRDA -$0.42 after Monday’s +$0.45),
  • uniQure NV (QURE -$0.32 after Monday’s -$0.76 after Friday’s -$0.54),
  • Supernus Therapeutics (SUPN -$0.14),
  • Cellectis SA (CLLS -$0.125 after Monday’s -$0.26),
  • Harvard Apparatus RT (OTCQB: HRGN -$0.08),
  • Compass Therapeutics (CMPX -$0.08),
  • Voyager Therapeutics (VYGR -$0.06),
  • Generation Bio (GBIO -$0.02),
  • Rocket Therapeutics (RCKT -$0.01),

 

The Bottom Line: More of the … WHY

US indexes rose to fresh records on Tuesday as investors continued to weigh US moves on Venezuela and braced for a flurry of fresh data this week to shed light on the health of the economy.

  • The S&P 500 closed at a record high, with the Nasdaq while the Dow climbed 1% to close above notched a back-to-back record.

 

For all my some say … RANTINGS, I say TRUTH TELLING… Capricor Therapeutics (CAPR) was UP +$1.53 or +6.17% Tuesday after being stripped of value in past sessions – their I Banks are executing the “PUMP” to protect the offering share pricing – DON’T be distracted – CONTINUE the SELL of the overbought.

 

Vertex Pharmaceuticals (VRTX) jumped 3.8% in the afternoon session after Wolfe Research upgraded the stock from "Peer Perform" to "Outperform" and issued a $548 price target.

  • The analyst firm pointed to a changing outlook for the company's potential treatment for IgA nephropathy (IgAN), a type of kidney disease. This positive view was based on several factors, including favorable pricing by a competitor and Vertex's plans to use a priority review voucher, which can speed up the drug approval process. The upgrade also reflected growing optimism around the upcoming results for its drug candidate, povetacicept, expected in early 2026. <StockStory>

 

The obesity market has garnered much interest lately, as both Eli Lilly and Novo Nordisk currently dominate this space with their injectable GLP-1 drugs.

  • According to research conducted by Goldman Sachs, the obesity market in the United States is expected to reach $100 billion by 2030. This is evident from the fact that LLY and NVO have not only optimized their production capacities but are also developing more potent and convenient GLP-1-based candidates in their clinical pipeline.

Eli Lilly and Novo Nordisk are racing to introduce oral weight-loss pills. NVO has already submitted a regulatory filing with the FDA seeking approval for an oral version of Wegovy, with a final decision expected before this year’s end.

  • It is also developing several next-generation candidates in its obesity pipeline, including CagriSema (a combination of semaglutide and cagrilintide) and an oral pill, amycretin (a dual GLP-1 and amylin receptor agonist). <Barrons>

Some good “additives”: An experimental drug from Arrowhead Pharmaceuticals (ARWR +9.46%) helped patients on Eli Lilly’s (LLY) +1.85%

  • Zepbound lose even more weight in a clinical trial, but big questions remain about how much patients will care.
  • ARWR’s experimental drug ARO-INHBE, combined with Zepbound, led to a 9.4% average weight loss in patients.
  • Patients on ARO-INHBE and Zepbound experienced a 23.3% reduction in visceral fat, compared to 7.4% for Zepbound alone.
  • Arrowhead’s ARO-ALK7 drug showed a 14.1% reduction in visceral fat after eight weeks in a separate trial.
  • The bigger winner on Tuesday was Wave Life Sciences (WVE +1.80%), an ARWR competitor that in December announced promising early data on a one-time treatment called WVE-007. Wave shares were up 23.7% Tuesday as investors took the ARWR data as a sign that Wave’s drug will work in similar future trials.
  • It’s all part of the next phase of the obesity market, created over the past few years by the arrival of Novo Nordisk’s (NOVO.B +4.99%) Wegovy and Lilly’s Zepbound. Together, the 2 drugs have created a massive new market for obesity treatments, with sales of Zepbound alone expected to have surpassed $13 billion in 2025, according to FactSet.
  • investors expressed enthusiasm around this result, as WVE-007 addresses the ‘biggest disadvantage’ of using popular GLP-1 therapies like Eli Lilly’s LLY Zepbound and Novo Nordisk’s NVO Wegovy — the loss of lean muscle mass. Wave Life Sciences also noted that the interim results support dosing once or twice a year — an added advantage over the LLY and NVO therapies, which require weekly administrations. <Barrons>

 

The recent profit-taking could also foreshadow some of the volatility ahead and …

  • RISK is always a factor remaining and … will boil-up under the surface until or as slight shocks rock the C&GT sector and markets!

As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

  • I would be following share pricing’s ascension on current biotech, cell and gene therapy sector upsides; so, some profiteering can be “situated” while maintaining a position, less elevated!

 

January – 2nd week’s session

  • 1/6 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1 /5 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

First week of January:

  • 1 /2 - Friday closed positive with 18 incliners, 17 decliners and 5 flats
  • 1/1 -Thursday was a holiday, New Years Day

Last week of December, Q4 and FY25

  • 12/31 -Wednesday closed negative with 18 positive, 22 negative and 5 flats
  • Tuesday closed negative with 7 positive, 31 negative and 2 flats
  • Monday closed negative with 12 positive, 24 negative and 4 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Tuesday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)
  • Monday: IQVIA Holdings (IQV), BioLife Solutions (BLFS), and Vericel (VCEL)
  • Last Friday: Alnylam Pharmaceuticals (ALNY), BioNTech (BNTX) and Arrowhead Pharmaceuticals (ARWER)

The worst three (3) in the session: Losers

  • Tuesday: AxoGen (AXGN), Ultragenyx Pharmaceuticals (RARE) and Entrada Therapeutics (TRDA)
  • Monday: Capricor Therapeutics (CAPR), Vertex (VRTX) and Arrowhead Pharmaceuticals (ARWR)
  • Last Friday: Vertex (VRTX), AxoGen (AXGN) and Wave Life Sciences (WVE)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.